Recent Data for PARP Inhibitors in Recurrent Ovarian Cancer
A detailed discussion focused on recent data on PARP inhibitors in the recurrent ovarian cancer setting.
A detailed discussion focused on recent data on PARP inhibitors in the recurrent ovarian cancer setting.
Abstract. Serine metabolism plays a pivotal role in cancer, making it an appealing therapeutic target. Two recent studies published in Nature Metabolism and Science Translational…
Abstract. Gain-of-function mutations in the histone acetylation ‘reader’ ENL, found in AML and Wilms tumor, are known to drive condensate formation and gene activation in…
Domenica Lorusso, MD, PhD, presents the final overall survival data from the randomized open -label phase 2 trial of relacorilant, a selective glucocorticoid receptor modulator…
An abstract is unavailable.
An Overview of MOA, Clinical Data, and Dosing Considerations
TWEAK secreted by Th17 cells promotes EMT by binding to Fn14 on colorectal cancer cells, suggesting that blocking the TWEAK-Fn14 interaction may be a promising…
Summary: . Pathogenic shifts in the gut microbiota are part of the “ecological” alterations that accompany tumor progression and compromise immunosurveillance. The future management of…
The phase 1 trial is evaluating MEM-288 in combination with nivolumab
Nivolumab monotherapy plus salvage nivolumab/ipilimumab demonstrated superior treatment-free survival rates among patients with advanced renal cell carcinoma, especially in patients with favorable risk profiles.
Moffitt gynecologic oncologist joins team of veterinarians and USF physicians to deliver an endangered Bornean orangutan via cesarean section.